1022 / 1851
Hybrid study:
SBRT with concurrent chemoradiation
•
Primary endpoint:
The Mean-lung dose (MLD)
associated with 15% chance
on radiation pneumonitis
≥G3 and dyspnea ≥G3
•
Secondary endpoints
:
Overall toxicity
Disease control
Study design
Endpoints
Courtesy of J. Belderbos